Frequently Asked Questions, page-17

Is RAC really that misunderstood by the market?

If you complete several hours of due diligence on RAC, and can see the enormous value of a drug that is the most potent FTO Inhibitor, that also potentially synergises with anti-PD1 therapy, that would also be first drug to market in that class, that also protects heart cells against chemotherapy, and that also has been significantly de-risked by decades of safety data… you’ll probably be doubting that RAC could be so undervalued by the market. You must have missed something, right?

Listen to the 18 Jan 2022 podcast from “Au$biz – The Call”. Commentary on RAC starts at 52:58. These market experts recommend NOT investing in RAC based on their research. Here are some insightful quotes:

• "Race Oncology, a pharmaceutical company, basically they have a chemotherapy drug called Bisantrene, and also another drug called Zantrene which is basically an obesity drug"
• "What I like about Race is they're not at the super, super, super bleeding edge of this, they're not trying to come up with new ideas"

If you can see just how monumentally uninformed these guys are, it’s not much of a stretch to see how RAC has been overlooked by the market, or been misled by ignorant stock analysts. Biotech is complex and confusing, but those who put in the time with comprehensive due diligence are rewarded with a valuable edge over others who don’t look past surface level.